WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 461635
Description: S 2720 is a human immunodeficiency virus type 1 (HIV-1)-specific reverse transcriptase (RT) inhibitor quinoxaline.
MedKoo Cat#: 461635
Name: S 2720
Chemical Formula: C14H15ClN2O2S
Exact Mass: 310.0543
Molecular Weight: 310.79
Elemental Analysis: C, 54.10; H, 4.86; Cl, 11.41; N, 9.01; O, 10.30; S, 10.32
This product is not in stock, which may be available by custom synthesis.
For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge).
Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.
Synonym: S 2720; S-2720; S2720;
IUPAC/Chemical Name: prop-1-en-2-yl 7-chloro-2,2-dimethyl-3-thioxo-3,4-dihydroquinoxaline-1(2H)-carboxylate
InChi Key: UNOJVGJCKUQAGH-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H15ClN2O2S/c1-8(2)19-13(18)17-11-7-9(15)5-6-10(11)16-12(20)14(17,3)4/h5-7H,1H2,2-4H3,(H,16,20)
SMILES Code: O=C(N1C(C)(C)C(NC2=C1C=C(Cl)C=C2)=S)OC(C)=C
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO
Shelf Life: >3 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.03.00
The following data is based on the product molecular weight 310.79 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1: Balzarini J, Karlsson A, Meichsner C, Paessens A, Riess G, De Clercq E, Kleim JP. Resistance pattern of human immunodeficiency virus type 1 reverse transcriptase to quinoxaline S-2720. J Virol. 1994 Dec;68(12):7986-92. PubMed PMID: 7525984; PubMed Central PMCID: PMC237261.
2: Kleim JP, Bender R, Billhardt UM, Meichsner C, Riess G, Rösner M, Winkler I, Paessens A. Activity of a novel quinoxaline derivative against human immunodeficiency virus type 1 reverse transcriptase and viral replication. Antimicrob Agents Chemother. 1993 Aug;37(8):1659-64. PubMed PMID: 7692812; PubMed Central PMCID: PMC188037.
3: Pelemans H, Esnouf R, Dunkler A, Parniak MA, Vandamme AM, Karlsson A, De Clercq E, Kleim JP, Balzarini J. Characteristics of the Pro225His mutation in human immunodeficiency virus type 1 (HIV-1) reverse transcriptase that appears under selective pressure of dose-escalating quinoxaline treatment of HIV-1. J Virol. 1997 Nov;71(11):8195-203. PubMed PMID: 9343170; PubMed Central PMCID: PMC192276.
4: Kleim JP, Bender R, Kirsch R, Meichsner C, Paessens A, Riess G. Mutational analysis of residue 190 of human immunodeficiency virus type 1 reverse transcriptase. Virology. 1994 May 1;200(2):696-701. PubMed PMID: 7513921.